Upstream Bio (UPB) FDA Approvals $8.46 +0.05 (+0.59%) Closing price 04:00 PM EasternExtended Trading$8.46 0.00 (0.00%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Upstream Bio's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Upstream Bio (UPB). Over the past two years, Upstream Bio has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Verekitug. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Verekitug FDA Regulatory Timeline and Events Verekitug is a drug developed by Upstream Bio for the following indication: In Chronic Obstructive Pulmonary Disease (COPD). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. New Data - May 18,2026New Data Phase 2Drug: VerekitugAnnounced Date: May 18, 2026Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. today presented new data from the Phase 2 VIBRANT trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP).AI SummaryUpstream Bio reported new Phase 2 VIBRANT trial data for verekitug in people with chronic rhinosinusitis with nasal polyps, or CRSwNP. The study included 81 participants, and about 60% also had asthma. In those with asthma, verekitug 100 mg given every 12 weeks improved asthma symptom control by Week 24, with a change in ACQ-6 that was better than placebo and greater than the level usually needed to matter to patients. Verekitug also improved nasal polyp scores in people with and without asthma. The treatment caused quick and lasting drops in type 2 inflammation markers, including blood eosinophils, which fell by 50% by Week 2 and stayed down through Week 24. IgE levels also declined over time. These results suggest verekitug may help both nasal and asthma symptoms in patients with CRSwNP.Read AnnouncementPoster Presentation - April 17,2026Poster Presentation Drug: VerekitugAnnounced Date: April 17, 2026Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026.AI SummaryUpstream Bio, Inc. announced it will present two poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The posters will showcase the company’s latest research findings and program updates and will be available for conference attendees to review. The presentations are aimed at clinicians, researchers, and others interested in respiratory and rare disease science. Upstream Bio plans to share data and insights from its ongoing work, and the posters may offer important details about the company’s development efforts for attendees and observers. Investor and media contact: Meggan Buckwell, Director, Corporate Communications and Investor Relations, [email protected]. Market News and Data brought to you by Benzinga APIs. © 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Read AnnouncementAdditional data - March 1,2026Additional Data Phase 2Drug: VerekitugAnnounced Date: March 1, 2026Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. presented additional data from the Phase 2 VIBRANT clinical trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP).Read AnnouncementLate Breaking Presentation - February 26,2026Late Breaking Presentation Drug: VerekitugAnnounced Date: February 26, 2026Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. announced an upcoming late-breaking poster session at the American Academy of Allergy, Asthma and Immunology (AAAAI) Congress 2026 in Philadelphia on Sunday, March 1, 2026.AI SummaryUpstream Bio, Inc. announced it will present late-breaking data at the American Academy of Allergy, Asthma and Immunology (AAAAI) Congress 2026 in Philadelphia on Sunday, March 1, 2026. New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) will be shown during a late-breaking poster session. Presentation title: "Efficacy and Safety of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps: Results of the Phase 2 VIBRANT Trial." The presenting author is Joseph Han, MD (Professor, Department of Otolaryngology & Head and Neck Surgery; Chief, Division of Allergy, Old Dominion University). Poster number L60, Late Breaking Poster Session II, Sunday, March 1, 2026, 9:45–10:45 a.m. EST, Convention Center, Level 2, Hall E. Verekitug is a novel recombinant fully human IgG1 monoclonal antibody that binds the thymic stromal lymphopoietin (TSLP) receptor and blocks proinflammatory signaling. It is the only known antagonist in clinical development that targets the TSLP receptor. Investor and media contact: Meggan Buckwell, Director, Corporate Communications and Investor Relations, [email protected].Read AnnouncementTop-line results - February 10,2026Top-Line Results Drug: VerekitugAnnounced Date: February 10, 2026Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc.announced it will report top-line results from the Phase 2 VALIANT trial of verekitug, the only known antagonist currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor, on Wednesday, February 11, 2026 at 8:00 a.m. ET.AI SummaryUpstream Bio, Inc. said it will release top-line results from the Phase 2 VALIANT trial of verekitug on Wednesday, February 11, 2026 at 8:00 a.m. ET. The company described verekitug as the only known antagonist currently in clinical development that directly targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor. The announcement covers the initial, high-level readout of the trial’s primary outcomes, which investors, clinicians and researchers will watch closely. TSLP is a signaling protein involved in airway and skin inflammation, so a drug that blocks its receptor could affect diseases such as asthma and atopic dermatitis. If the VALIANT top-line results are positive, Upstream Bio could advance verekitug toward later-stage testing and broader clinical use. The February update will give the first clear public view of how well the drug performed in this mid-stage study.Read AnnouncementData - September 30,2025Data Drug: VerekitugAnnounced Date: September 30, 2025Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc today presented structural and mechanistic data showing verekitug's potent pharmacodynamic activity through its unique approach of targeting the thymic stromal lymphopoietin (TSLP) receptor.AI SummaryUpstream Bio presented new data showing how verekitug blocks the inflammatory signal TSLP by targeting its receptor. High-resolution crystal structures reveal verekitug binds and occupies key TSLP binding sites on the receptor. Even when the receptor is already paired, verekitug outcompetes TSLP and prevents it from activating the receptor. Mechanistic studies found that verekitug’s binding strength is extremely high (KD < 1 pM). Pharmacokinetic and pharmacodynamic models suggest the TSLP receptor is less abundant and turns over more slowly than the TSLP protein itself. This combination helps explain why verekitug shows greater potency compared to therapies that only target the TSLP ligand. These findings support the idea that targeting the TSLP receptor could lead to stronger, longer-lasting effects in severe respiratory diseases. Early clinical trials have already shown rapid and durable receptor inhibition for up to 24 weeks after a dose. Phase 2 top-line data in severe asthma is expected in early 2026.Read AnnouncementTop-line results - September 2,2025Top-Line Results Phase 2Drug: VerekitugAnnounced Date: September 2, 2025Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. announced positive top-line results from the Phase 2 VIBRANT trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP). Verekitug is the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP).AI SummaryUpstream Bio, Inc. announced positive top-line results from its Phase 2 VIBRANT trial evaluating verekitug, a new monoclonal antibody medicine, in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). The trial tested whether monthly injections of verekitug could reduce nasal polyps and ease symptoms like congestion and loss of smell. The study met its primary endpoint by showing a significant drop in total nasal polyp score compared with placebo. Patients also reported improvements on symptom scales, and many saw better breathing and smell recovery. Verekitug was generally safe and well tolerated, with most side effects mild to moderate. Verekitug is the only clinical-stage antibody known to target the receptor for thymic stromal lymphopoietin (TSLP), a key molecule in airway inflammation. Upstream Bio plans to start Phase 3 studies later this year to confirm these promising results.Read AnnouncementTop-line data - September 1,2025Top-Line Data Phase 2Drug: VerekitugAnnounced Date: September 1, 2025Target Action Date: September 2, 2025Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025.AI SummaryUpstream Bio, Inc., a clinical-stage biotechnology company focused on inflammatory and severe respiratory diseases, said it will present top-line data on Tuesday, September 2, 2025, from its Phase 2 VIBRANT trial of verekitug, the only clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP). TSLP drives inflammation in several immune conditions. The VIBRANT trial is a global, randomized, placebo-controlled study in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). Participants received 100 mg of verekitug or placebo by subcutaneous injection every 12 weeks for 24 weeks. The primary goal is change in the endoscopic nasal polyp score at Week 24. Upstream Bio will host a conference call and live webcast on Tuesday, September 2, 2025 at 8:00 a.m. ET to discuss the results. Investors can join the webcast via the Events tab on the company’s website, and a replay will be available afterward.Read AnnouncementDose Update - July 8,2025Dose Update Phase 2Drug: VerekitugAnnounced Date: July 8, 2025Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. announced that the first patient has been dosed in the Company's Phase 2 clinical trial evaluating verekitug in patients with COPD, broadening the global development program for verekitug into a third indication.AI SummaryUpstream Bio, Inc. announced that the first patient has been dosed in its global Phase 2 VENTURE trial evaluating verekitug for COPD, marking a significant step as the drug enters a third indication. Verekitug is a novel antibody that targets the TSLP receptor, which plays a key role in triggering inflammation. The trial is a randomized, double-blind, placebo-controlled study designed to assess both the efficacy and safety of two dosing regimens—100 mg every 12 weeks and 400 mg every 24 weeks—in approximately 670 adults with moderate-to-severe COPD. This trial expands the company’s efforts beyond its ongoing studies in severe asthma and chronic rhinosinusitis with nasal polyps. Emerging data suggest that targeting TSLP may offer a differentiated approach to treating COPD, potentially reducing the frequency of exacerbations and improving patient outcomes.Read Announcement Upstream Bio FDA Events - Frequently Asked Questions Has Upstream Bio received FDA approval? As of now, Upstream Bio (UPB) has not received any FDA approvals for its therapy in the last two years. What drugs has Upstream Bio submitted to the FDA? In the past two years, Upstream Bio (UPB) has reported FDA regulatory activity for Verekitug. What is the most recent FDA event for Upstream Bio? The most recent FDA-related event for Upstream Bio occurred on May 18, 2026, involving Verekitug. The update was categorized as "New Data," with the company reporting: "Upstream Bio, Inc. today presented new data from the Phase 2 VIBRANT trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP)." What conditions do Upstream Bio's current drugs treat? Currently, Upstream Bio has one therapy (Verekitug) targeting the following condition: In Chronic Obstructive Pulmonary Disease (COPD). More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Adagio Medical FDA EventsBioCardia FDA EventsCognition Therapeutics FDA EventsCorbus Pharmaceuticals FDA EventsPrecision BioSciences FDA EventsHUTCHMED FDA EventsEli Lilly and Company FDA EventsTeleflex FDA EventsBioMarin Pharmaceutical FDA EventsDiaMedica Therapeutics FDA EventsDyne Therapeutics FDA EventsGuardant Health FDA EventsLigand Pharmaceuticals FDA EventsMadrigal Pharmaceuticals FDA EventsMetaVia FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies AnaptysBio FDA Events Taysha Gene Therapies FDA Events Pharvaris FDA Events MBX Biosciences FDA Events Syndax Pharmaceuticals FDA Events Mesoblast FDA Events Inhibrx Biosciences FDA Events Capricor Therapeutics FDA Events Rapport Therapeutics FDA Events Lakefront Biotherapeutics American Depositary Shares FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:UPB last updated on 5/19/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
New Data - May 18,2026New Data Phase 2Drug: VerekitugAnnounced Date: May 18, 2026Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. today presented new data from the Phase 2 VIBRANT trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP).AI SummaryUpstream Bio reported new Phase 2 VIBRANT trial data for verekitug in people with chronic rhinosinusitis with nasal polyps, or CRSwNP. The study included 81 participants, and about 60% also had asthma. In those with asthma, verekitug 100 mg given every 12 weeks improved asthma symptom control by Week 24, with a change in ACQ-6 that was better than placebo and greater than the level usually needed to matter to patients. Verekitug also improved nasal polyp scores in people with and without asthma. The treatment caused quick and lasting drops in type 2 inflammation markers, including blood eosinophils, which fell by 50% by Week 2 and stayed down through Week 24. IgE levels also declined over time. These results suggest verekitug may help both nasal and asthma symptoms in patients with CRSwNP.Read Announcement
Poster Presentation - April 17,2026Poster Presentation Drug: VerekitugAnnounced Date: April 17, 2026Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026.AI SummaryUpstream Bio, Inc. announced it will present two poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The posters will showcase the company’s latest research findings and program updates and will be available for conference attendees to review. The presentations are aimed at clinicians, researchers, and others interested in respiratory and rare disease science. Upstream Bio plans to share data and insights from its ongoing work, and the posters may offer important details about the company’s development efforts for attendees and observers. Investor and media contact: Meggan Buckwell, Director, Corporate Communications and Investor Relations, [email protected]. Market News and Data brought to you by Benzinga APIs. © 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Read Announcement
Additional data - March 1,2026Additional Data Phase 2Drug: VerekitugAnnounced Date: March 1, 2026Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. presented additional data from the Phase 2 VIBRANT clinical trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP).Read Announcement
Late Breaking Presentation - February 26,2026Late Breaking Presentation Drug: VerekitugAnnounced Date: February 26, 2026Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. announced an upcoming late-breaking poster session at the American Academy of Allergy, Asthma and Immunology (AAAAI) Congress 2026 in Philadelphia on Sunday, March 1, 2026.AI SummaryUpstream Bio, Inc. announced it will present late-breaking data at the American Academy of Allergy, Asthma and Immunology (AAAAI) Congress 2026 in Philadelphia on Sunday, March 1, 2026. New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) will be shown during a late-breaking poster session. Presentation title: "Efficacy and Safety of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps: Results of the Phase 2 VIBRANT Trial." The presenting author is Joseph Han, MD (Professor, Department of Otolaryngology & Head and Neck Surgery; Chief, Division of Allergy, Old Dominion University). Poster number L60, Late Breaking Poster Session II, Sunday, March 1, 2026, 9:45–10:45 a.m. EST, Convention Center, Level 2, Hall E. Verekitug is a novel recombinant fully human IgG1 monoclonal antibody that binds the thymic stromal lymphopoietin (TSLP) receptor and blocks proinflammatory signaling. It is the only known antagonist in clinical development that targets the TSLP receptor. Investor and media contact: Meggan Buckwell, Director, Corporate Communications and Investor Relations, [email protected].Read Announcement
Top-line results - February 10,2026Top-Line Results Drug: VerekitugAnnounced Date: February 10, 2026Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc.announced it will report top-line results from the Phase 2 VALIANT trial of verekitug, the only known antagonist currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor, on Wednesday, February 11, 2026 at 8:00 a.m. ET.AI SummaryUpstream Bio, Inc. said it will release top-line results from the Phase 2 VALIANT trial of verekitug on Wednesday, February 11, 2026 at 8:00 a.m. ET. The company described verekitug as the only known antagonist currently in clinical development that directly targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor. The announcement covers the initial, high-level readout of the trial’s primary outcomes, which investors, clinicians and researchers will watch closely. TSLP is a signaling protein involved in airway and skin inflammation, so a drug that blocks its receptor could affect diseases such as asthma and atopic dermatitis. If the VALIANT top-line results are positive, Upstream Bio could advance verekitug toward later-stage testing and broader clinical use. The February update will give the first clear public view of how well the drug performed in this mid-stage study.Read Announcement
Data - September 30,2025Data Drug: VerekitugAnnounced Date: September 30, 2025Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc today presented structural and mechanistic data showing verekitug's potent pharmacodynamic activity through its unique approach of targeting the thymic stromal lymphopoietin (TSLP) receptor.AI SummaryUpstream Bio presented new data showing how verekitug blocks the inflammatory signal TSLP by targeting its receptor. High-resolution crystal structures reveal verekitug binds and occupies key TSLP binding sites on the receptor. Even when the receptor is already paired, verekitug outcompetes TSLP and prevents it from activating the receptor. Mechanistic studies found that verekitug’s binding strength is extremely high (KD < 1 pM). Pharmacokinetic and pharmacodynamic models suggest the TSLP receptor is less abundant and turns over more slowly than the TSLP protein itself. This combination helps explain why verekitug shows greater potency compared to therapies that only target the TSLP ligand. These findings support the idea that targeting the TSLP receptor could lead to stronger, longer-lasting effects in severe respiratory diseases. Early clinical trials have already shown rapid and durable receptor inhibition for up to 24 weeks after a dose. Phase 2 top-line data in severe asthma is expected in early 2026.Read Announcement
Top-line results - September 2,2025Top-Line Results Phase 2Drug: VerekitugAnnounced Date: September 2, 2025Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. announced positive top-line results from the Phase 2 VIBRANT trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP). Verekitug is the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP).AI SummaryUpstream Bio, Inc. announced positive top-line results from its Phase 2 VIBRANT trial evaluating verekitug, a new monoclonal antibody medicine, in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). The trial tested whether monthly injections of verekitug could reduce nasal polyps and ease symptoms like congestion and loss of smell. The study met its primary endpoint by showing a significant drop in total nasal polyp score compared with placebo. Patients also reported improvements on symptom scales, and many saw better breathing and smell recovery. Verekitug was generally safe and well tolerated, with most side effects mild to moderate. Verekitug is the only clinical-stage antibody known to target the receptor for thymic stromal lymphopoietin (TSLP), a key molecule in airway inflammation. Upstream Bio plans to start Phase 3 studies later this year to confirm these promising results.Read Announcement
Top-line data - September 1,2025Top-Line Data Phase 2Drug: VerekitugAnnounced Date: September 1, 2025Target Action Date: September 2, 2025Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025.AI SummaryUpstream Bio, Inc., a clinical-stage biotechnology company focused on inflammatory and severe respiratory diseases, said it will present top-line data on Tuesday, September 2, 2025, from its Phase 2 VIBRANT trial of verekitug, the only clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP). TSLP drives inflammation in several immune conditions. The VIBRANT trial is a global, randomized, placebo-controlled study in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). Participants received 100 mg of verekitug or placebo by subcutaneous injection every 12 weeks for 24 weeks. The primary goal is change in the endoscopic nasal polyp score at Week 24. Upstream Bio will host a conference call and live webcast on Tuesday, September 2, 2025 at 8:00 a.m. ET to discuss the results. Investors can join the webcast via the Events tab on the company’s website, and a replay will be available afterward.Read Announcement
Dose Update - July 8,2025Dose Update Phase 2Drug: VerekitugAnnounced Date: July 8, 2025Indication: In Chronic Obstructive Pulmonary Disease (COPD)AnnouncementUpstream Bio, Inc. announced that the first patient has been dosed in the Company's Phase 2 clinical trial evaluating verekitug in patients with COPD, broadening the global development program for verekitug into a third indication.AI SummaryUpstream Bio, Inc. announced that the first patient has been dosed in its global Phase 2 VENTURE trial evaluating verekitug for COPD, marking a significant step as the drug enters a third indication. Verekitug is a novel antibody that targets the TSLP receptor, which plays a key role in triggering inflammation. The trial is a randomized, double-blind, placebo-controlled study designed to assess both the efficacy and safety of two dosing regimens—100 mg every 12 weeks and 400 mg every 24 weeks—in approximately 670 adults with moderate-to-severe COPD. This trial expands the company’s efforts beyond its ongoing studies in severe asthma and chronic rhinosinusitis with nasal polyps. Emerging data suggest that targeting TSLP may offer a differentiated approach to treating COPD, potentially reducing the frequency of exacerbations and improving patient outcomes.Read Announcement
